• Title of article

    Abrogation of the p38 MAPK α signaling pathway does not promote radioresistance but its activity is required for 5-Fluorouracil-associated radiosensitivity

  • Author/Authors

    de la Cruz-Morcillo، نويسنده , , Miguel A. and Garcيa-Cano، نويسنده , , Jesْs and Arias-Gonzلlez، نويسنده , , Laura and Garcيa-Gil، نويسنده , , Elena and Artacho-Cordَn، نويسنده , , Francisco and Rيos-Arrabal، نويسنده , , Sandra and Valero، نويسنده , , Marيa L. and Cimas، نويسنده , , Francisco J. and Serrano-Oviedo، نويسنده , , Leticia and Villas، نويسنده , , Marيa V. and Romero-Fernلndez، نويسنده , , Jesْs and Nٌْez، نويسنده , , Marيa I. and Sلnchez-Prieto، نويسنده , , Ricardo، نويسنده ,

  • Issue Information
    روزنامه با شماره پیاپی سال 2013
  • Pages
    9
  • From page
    66
  • To page
    74
  • Abstract
    The p38 Mitogen Activated Protein Kinase (MAPK) signaling pathway has become a major player in the response to DNA-damage. A growing body of evidences has been relating this signaling pathway to the cellular response to ionizing radiation (IR), suggesting a role in radioresistance. Here, we study the implication of this signaling pathway in the response to IR in terms of radioresistance. To this end we used 10 different cell lines derived from several types of tumors (colorectal, non-small cell lung cancer -NSCLC-, renal and glioblastoma). Although p38 MAPK is transiently activated by IR, our data, obtained by genetic and chemical approaches, showed that this signaling pathway is not implicated in cellular viability after IR exposure. Indeed, down-modulation of this signaling pathway promotes a mild radiosensitivity depending on the cell line. However, it is remarkable that lack of p38 MAPK α abrogates the radiosensitizing effect of 5-Fluorouracil (5-FU) in HCT116 cell line, supporting the role of this MAPK in the radiosensitizing action of 5-FU.
  • Keywords
    p38 MAPK , radioresistance , SB203580 , 5-fluorouracil
  • Journal title
    Cancer Letters
  • Serial Year
    2013
  • Journal title
    Cancer Letters
  • Record number

    1822952